Kimberly-Clark to Acquire Kenvue for $48.7 Billion, Offering Immediate Liquidity and Long-Term Upside

Kimberly-Clark agreed to acquire Kenvue in a $48.7 billion deal, valuing the consumer health company at a 50% premium. Kenvue shareholders will receive $3.50 per share in cash and KMB stock, unlocking $2.1 billion in synergies. Despite a 15% surge, Kenvue stock is down over 30% YTD. Analysts and investor Jim Cramer see the deal as positive for KVUE shares, citing operational upside and long-term potential.